Accepted for/Published in: JMIR Human Factors
Date Submitted: Mar 29, 2021
Open Peer Review Period: Mar 29, 2021 - Apr 5, 2021
Date Accepted: Aug 25, 2021
Date Submitted to PubMed: Aug 30, 2021
(closed for review but you can still tweet)
Automated and Closed Loop Oncology Agent Compounding and Administration; Gains in Safety and Efficiency.
ABSTRACT
Background:
The forms of automation available to the oncology pharmacy range from compounding robotic solutions, through to combination workflow software which can scale up to cover the entire workflow from prescribing to administration. A solution that offers entire workflow management for oncology is desirable because in terms of cytotoxic delivery of a regimen to a patient the chain, which starts with prescription and the assay of the patient’s laboratory results and ends with administration, has multiple potential chokepoints.
Objective:
To show how incremental change to a core compounding workflow software solution has helped an organization meet goals of improved patient safety, increasing the number of oncology treatments, improving documentation and improving communication between oncologists, pharmacists and nurses. And to illustrate how using this technology flow beyond the pharmacy has extended medication safety to the patient’s bedside through the deployment of a connected solution for confirming, and documenting, right patient-right medication transactions.
Methods:
A compounding workflow software solution was introduced for both preparation and documentation, with pharmacist verification of the order, gravimetric checks, and step-by-step on-screen instructions displayed in the work area for the technician. The software supported the technician during compounding by proposing required drug vial size, diluents and consumables. Out of tolerance concentrations were auto-alerted via an integrated gravimetric scale. A patient-medication label was created. Integration was undertaken between a prescribing module and the compounding module to reduce the risk of transcription errors. The deployment of wireless connected handheld barcode scanners was then made to allow nurses to use the patient-medication label on each compounded product and to scan patient ID bands to ensure right patient-right prescription.
Results:
Despite an increase in compounding, with a growth of 12% per annum and no increase in pharmacy headcount we doubled our output to 14,000 medications per annum through application of the compounding solution. There was also an overall reduction in compounding time of 35%. We also saw improved management of remnants and reduced costs overall. The use of handheld barcode scanning for nurses reduced the time for medication administration from ≈ 6 minutes per item to 41 seconds, with a mean average saving of 5 minutes and 19 seconds (5.303 minutes) per item. When calculated against our throughput of 14,000 items per annum (current production rate via pharmacy) this gives a saving of 3 Hours and 24 minutes of nursing time per day, equivalent to 0.425 full-time nurses per annum.
Conclusions:
The addition of prescribing, compounding and administration software solutions to our oncology mediation chain has increased detection and decreased the risk of error at each stage of the process. The double-checks that the system has built in by virtue of its own systems and through the flow of control of drugs and dosages from physician to pharmacist to nurse allows it to integrate fully with our human systems of risk management. Clinical Trial: Nil
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.